DetailsCategory: Small MoleculesPublished on Wednesday, 12 February 2020 17:52Hits: 446
PLEASANTON, CA, USA I February 11, 2020 I Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Japan, today announced that the U.S. FDA has accepted for Priority Review its NDA for oral C-DEC (cedazuridine and decitabine) as a treatment for adults with previously untreated intermediate- and high-risk MDS including CMML. The NDA submission is based on data from the ASCERTAIN phase 3 study which evaluated the 5-day decitabine exposure equivalence of oral C-DEC and IV decitabine.
We are very pleased that the FDA has accepted our NDA for Priority Review, said Dr Mohammad Azab, MD, president & chief medical officer of Astex Pharmaceuticals, Inc. Subject to FDA review and regulatory approval, oral C-DEC may offer a new option for patients with MDS and CMML that saves them the burden of 5-day IV infusions every month during their treatment period. We are grateful to all the patients, investigators and other healthcare providers, and partner research and manufacturing organizations, who contributed to the clinical development program of oral C-DEC.
The FDA grants Priority Review to applications for drugs that, if approved, would provide significant improvements in the safety and effectiveness of the treatment, diagnosis or prevention of serious conditions. The Priority Review designation means FDAs goal is to take action on an NDA application within six months (compared to the ten months under standard review).
Oral C-DEC is an investigational compound and is not currently approved in any country.
Astexs parent company, Otsuka Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. previously announced that, subject to regulatory approvals, commercialization of oral C-DEC in the U.S. and Canada will be conducted by Taiho Oncology, Inc. and Taiho Pharma Canada, Inc. respectively. Astex, Otsuka and Taiho are all members of the Otsuka group of companies.
About C-DEC (Cedazuridine 100 mg and Decitabine 35 mg) Fixed-Dose Combination
C-DEC is a novel, orally administered fixed dose combination of cedazuridine, an inhibitor of cytidine deaminase,1 with the anti-cancer DNA hypomethylating agent, decitabine.2 By inhibiting cytidine deaminase in the gut and the liver, C-DEC is designed to allow for oral delivery of the approved DNA hypomethylating agent, decitabine, at exposures which emulate exposures achieved with the approved intravenous form of decitabine administered over 5 days.3
C-DEC has been evaluated in a phase 1/2 pharmacokinetics-guided dose escalation and dose confirmation study in patients with MDS and CMML (see https://www.clinicaltrials.gov NCT02103478) and a pivotal phase 3 study (ASCERTAIN) (see https://www.clinicaltrials.gov NCT03306264) conducted at investigator sites in the US and Canada and designed to confirm the results from the phase 1/2 study. The phase 3 study is now being extended to include patients with acute myeloid leukemia (AML) unsuitable to receive intensive induction chemotherapy.
In September 2019 Astex announced that C-DEC had received orphan drug designation for the treatment of MDS and CMML from the U.S. FDA.
The concept of using cedazuridine to block the action of cytidine deaminase is also being evaluated in a low dose formulation of cedazuridine and decitabine for the treatment of lower risk MDS (see https://www.clinicaltrials.gov NCT03502668).
About the Phase 3 ASCERTAIN Study
The study was designed as a randomized crossover study comparing oral C-DEC (cedazuridine 100 mg and decitabine 35 mg fixed-dose combination tablet given once daily for 5 days on a 28-day cycle) to IV decitabine (20 mg/m2 administered as a daily, 1-hour IV infusion for 5 days on a 28-day cycle) in the first 2 cycles with patients continuing to receive oral C-DEC from Cycle 3 onwards. The data from the ASCERTAIN study was presented at the American Society of Hematology (ASH) Meeting in Orlando, Florida in December 2019 by Dr Guillermo Garcia-Manero, MD, professor and chief of section of myelodysplastic syndromes, Department of Leukemia at The University of Texas MD Anderson Cancer Center, on behalf of the study investigators.4 The data demonstrated that the ASCERTAIN study met the primary endpoint of total 5-Day decitabine Area-Under-The-Curve (AUC) equivalence of oral C-DEC and IV decitabine. Safety findings from the study were consistent with those anticipated with IV decitabine, with no significant differences in the incidence of most common adverse events between oral C-DEC and IV decitabine in the first 2 randomized cycles. The most common adverse events of any grade >20% regardless of causality in patients in the first 2 randomized cycles who received oral C-DEC were thrombocytopenia (43.8%), neutropenia (35.4%), anemia (36.9%), and fatigue (23.8%). The ASH presentation can be downloaded from the Astex website at https://astx.com/media-center/presentations-and-publications/ASTX727 ASCERTAIN Presentation - ASH - December 2019
About Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by dysplastic changes in myeloid, erythroid, and megakaryocytic progenitor cells, and associated with cytopenias affecting one or more of the three lineages. U.S. incidence of MDS is estimated to be 10,000 cases per year, although the condition is thought to be under-diagnosed.5,6 The prevalence has been estimated to be from 60,000 to 170,000 in the U.S.7 MDS may evolve into acute myeloid leukemia (AML) in one-third of patients.8 The prognosis for MDS patients is poor; patients die from complications associated with cytopenias (infections and bleeding) or from transformation to AML. CMML is a clonal hematopoietic malignancy characterized by accumulation of abnormal monocytes in the bone marrow and in blood. The incidence of CMML in the U.S. is approximately 1,100 new cases per year,9 and CMML may transform into AML in 15% to 30% of patients.10 The hypomethylating agents decitabine and azacitidine are effective treatment modalities for hematologic cancers and are FDA-approved for the treatment of higher-risk MDS and CMML. These agents are administered by IV infusion, or by large-volume subcutaneous injections.
About Astex Pharmaceuticals, Inc.
Astex is a leader in innovative drug discovery and development, committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies and has multiple partnered products in development under collaborations with leading pharmaceutical companies. Astex is a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan.
Otsuka is a global healthcare company with the corporate philosophy: Otsukapeople creating new products for better health worldwide. Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
For more information about Astex Pharmaceuticals, Inc. please visit: http://www.astx.com
For more information about Otsuka Pharmaceutical, please visit: http://www.otsuka.com/en/
For more information about Taiho Pharmaceutical, please visit: https://www.taihooncology.com/
References
SOURCE: Astex Pharmaceuticals
Read this article:
Astex Pharmaceuticals Announces US Food and Drug Administration (FDA) Acceptance for Review of an NDA for the Combination Oral Hypomethylating Agent...
- UC Irvine Study Reveals Risks Associated with Direct-to-Consumer Ads for Stem Cell and Exosome COVID-19 Therapies - India Education Diary - November 18th, 2023
- STEM | Description, Development, & Facts | Britannica - January 31st, 2023
- What is STEM Education? | Live Science - January 31st, 2023
- Science, Technology, Engineering, and Math, including Computer Science - ed - January 23rd, 2023
- What Does STEM Stand For? Definition, Degrees and More - January 23rd, 2023
- What Is STEM? - Definition & Resources for Teachers - January 23rd, 2023
- Science, technology, engineering, and mathematics - Wikipedia - January 23rd, 2023
- Stem Definition & Meaning - Merriam-Webster - January 23rd, 2023
- November: labblood-study | News and features - University of Bristol - November 7th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 7th, 2022
- Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and... - November 7th, 2022
- Type 2 Diabetes Stem Cell Therapy - Top U.S. Stem Cell ... - January 1st, 2022
- Cancer Drug Approvals from 2021 That Patients May Have Missed - Curetoday.com - January 1st, 2022
- Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation - DocWire News - January 1st, 2022
- The new life of a teenager with a strange tumor on his face after the operation - Market Research Telecast - January 1st, 2022
- Best of what was new in diabetes health for 2021 - Dickson Post - January 1st, 2022
- Hematopoietic Stem Cell Transplantation - StatPearls ... - December 22nd, 2021
- Autologous Stem Cell Transplant for Multiple Myeloma - December 22nd, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 22nd, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 22nd, 2021
- FDA Approves First Drug to Prevent Graft Versus Host Disease | FDA - FDA.gov - December 22nd, 2021
- Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients - Yahoo Finance - December 22nd, 2021
- After throwing goodbye party, woman with cancer finds hope close to home in Austin - Austin American-Statesman - December 22nd, 2021
- Dr. K.M. Cherian Heart Foundation & Educational Society Organized Cme Programme & Workshop On Cell Culture And Regenerative Medicine - APN... - December 22nd, 2021
- Namesake of new center a young man in love with the pursuit of knowledge - The Saint Anselm Crier - November 7th, 2021
- Red Cross blood drive focuses on sickle cell disease fight - Palladium-Item - November 7th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - KULR-TV - November 7th, 2021
- 1st CRISPR Gene Editing Trial Slated to Open in Severe SCD Patients - Sickle Cell Anemia News - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Timely Bone Marrow Transplant by Fortis gives new lease of life to a patient with Multiple Myeloma - APN News - April 4th, 2021
- Kirron Kher is suffering with Multiple Myeloma: Know the causes, symptoms and more about this type of blood cancer - Jagran English - April 4th, 2021
- Decitabine Improved Outcomes for Patients With Refractory Prolonged Isolated Thrombocytopenia - Hematology Advisor - April 4th, 2021
- Lake in the Hills police officer and father of 4 kids battling rare cancer forced to retire - Lake and McHenry County Scanner - April 4th, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 4th, 2021
- Boxcar Scars Market |Exclusive Report on Latest Trends and Market Growth Opportunities - BioSpace - April 4th, 2021
- Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult... - April 4th, 2021
- BeyondSpring Announces Submission of New Drug Application to US FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of... - April 4th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 14th, 2021
- Roche receives first FDA clearance for urine sample type for BK virus quantitative test to aid in the improvement of care for transplant patients -... - February 14th, 2021
- Energy drinks may damage the heart, researchers warnshould the FDA get involved? - Cardiovascular Business - February 14th, 2021
- FDA Approves G1 Therapeutics' COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced... - February 14th, 2021
- Easter Ross mum of blood cancer tot urges would-be stem cell donors to show the love this Valentine's Day; Alness lass Adeline Davidson's plight... - February 14th, 2021
- Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas... - February 14th, 2021
- Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Understanding bone marrow transplant: The guidelines and the protocols - The New Indian Express - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Mobilize family caregivers to speed the rollout of Covid-19 vaccines - STAT - February 4th, 2021
- People With Cancer Should Receive COVID-19 Vaccine, Experts Say - Cancer Health Treatment News - February 4th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f - PharmiWeb.com - February 4th, 2021
- APOE Tied to Increased Susceptibility to SARS-CoV-2 | ALZFORUM - Alzforum - February 4th, 2021
- Transforming Outcomes in Advanced CSCC with Immunotherapy - LWW Journals - February 4th, 2021
- Ashley Cain is living his worst nightmare as his baby daughter battles leukaemia in hospital - The Sun - February 4th, 2021
- Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca - February 1st, 2021
- Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth... - February 1st, 2021
- Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical... - February 1st, 2021
- Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA... - February 1st, 2021
- Disabled People Are Waiting, Anxiously, For Lifesaving Covid-19 Vaccinations - Forbes - February 1st, 2021
- Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph - February 1st, 2021
- Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation - Science Advances - February 1st, 2021
- The Need for New Biological Targets for Therapeutic Intervention in COPD - Pulmonology Advisor - February 1st, 2021
- What Patients With Cancer, Survivors Need to Know About the Emergency Use Authorization of COVID-19 Vaccine - Curetoday.com - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- Are Hiccups a Sign of the New Coronavirus? - Healthline - December 19th, 2020
- KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective... - December 19th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 19th, 2020
- Even if You've Had COVID-19 You Still Need the Vaccine - Healthline - December 19th, 2020
- The Link Between Cancer and Metabolic Dysfunction - Technology Networks - December 19th, 2020
- Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -... - December 19th, 2020
- Gene therapy gives man with sickle cell disease the chance for a better future - Science Codex - December 3rd, 2020
- Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous... - December 3rd, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 3rd, 2020
- Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed - December 3rd, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary - December 3rd, 2020
- Coinfection: more than the sum of its parts - Science Codex - November 19th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 17th, 2020
- FDA Approves Merck's KEYTRUDA in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple?Negative Breast... - November 17th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 17th, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 17th, 2020
- UH announces participation in clinical trial testing antibodies to treat COVID-19 in adults - News 5 Cleveland - November 7th, 2020